Opinion - Angiogenesis: an organizing principle for drug discovery?

被引：1788

作者：

Folkman, Judah ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2007年 / 6卷 / 04期

关键词：

ENDOTHELIAL GROWTH-FACTOR; ANTIANGIOGENIC THERAPY; BREAST-CANCER; TUMOR-GROWTH; ENDOGENOUS INHIBITORS; INTERFERON-ALPHA; FACTOR VEGF; MATRIX METALLOPROTEINASES; INTRAVITREAL INJECTION; TARGETING ANGIOGENESIS;

D O I：

10.1038/nrd2115

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 090105 [作物生产系统与生态工程];

摘要：

Angiogenesis - the process of new blood-vessel growth - has an essential role in development, reproduction and repair. However, pathological angiogenesis occurs not only in tumour formation, but also in a range of nonneoplastic diseases that could be classed together as 'angiogenesis-dependent diseases'. By viewing the process of angiogenesis as an 'organizing principle' in biology, intriguing insights into the molecular mechanisms of seemingly unrelated phenomena might be gained. This has important consequences for the clinical use of angiogenesis inhibitors and for drug discovery, not only for optimizing the treatment of cancer, but possibly also for developing therapeutic approaches for various diseases that are otherwise unrelated to each other.

引用

页码：273 / 286

页数：14

共 141 条

[1]

Endostatin's antiangiogenic signaling network [J].

Abdollahi, A ;

Hahnfeldt, P ;

Maercker, C ;

Gröne, HJ ;

Debus, J ;

Ansorge, W ;

Folkman, J ;

Hlatky, L ;

Huber, PE .

MOLECULAR CELL, 2004, 13 (05) :649-663

[2]

Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis [J].

Almog, Nava ;

Henke, Vanessa ;

Flores, Ludmila ;

Hlatky, Lynn ;

Kung, Andrew L. ;

Wright, Renee D. ;

Berger, Raanan ;

Hutchinson, Lloyd ;

Naumov, George N. ;

Bender, Elise ;

Akslen, Lars A. ;

Achilles, Eike-Gert ;

Folkman, Judah .

FASEB JOURNAL, 2006, 20 (07) :947-+

[3]

TUMOR-INDUCED ANGIOGENESIS - LACK OF INHIBITION BY IRRADIATION [J].

AUERBACH, R ;

ARENSMAN, R ;

KUBAI, L ;

FOLKMAN, J .

INTERNATIONAL JOURNAL OF CANCER, 1975, 15 (02) :241-245

[4]

AUSPRUNK DH, 1978, LAB INVEST, V38, P284

[5]

AUSPRUNK DH, 1975, AM J PATHOL, V79, P597

[6]

Evidence by molecular profiling for a placental origin of infantile hemangioma [J].

Barnés, CM ;

Huang, S ;

Kaipainen, A ;

Sanoudou, D ;

Chen, EJ ;

Eichler, GS ;

Guo, YC ;

Yu, Y ;

Ingber, DE ;

Mulliken, JB ;

Beggs, AH ;

Folkman, J ;

Fishman, SJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (52) :19097-19102

[7]

Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice [J].

Beecken, WDC ;

Fernandez, A ;

Joussen, AM ;

Achilles, EG ;

Flynn, E ;

Lo, KM ;

Gillies, SD ;

Javaherian, K ;

Folkman, J ;

Shing, Y .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (05) :382-387

[8]

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy [J].

Bocci, G ;

Francia, G ;

Man, S ;

Lawler, J ;

Kerbel, RS .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (22) :12917-12922

[9]

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [J].

Boehm, T ;

Folkman, J ;

Browder, T ;

OReilly, MS .

NATURE, 1997, 390 (6658) :404-407

[10]

Browder T, 2000, CANCER RES, V60, P1878

← 1 2 3 4 5 6 7 8 9 10 →